Non-small-cell lung cancer: how to manage MET exon 14 skipping mutant disease

• Asıl Yazarlar: Juan Bautista Blaquier (Yazar), Gonzalo Recondo (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: BioExcel Publishing Ltd, 2022-06-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Several oncogenic mechanisms have been identified for MET, including MET amplification, fusions, mutations in the tyrosine kinase domain and exon 14 skipping alterations. MET exon 14 mutations are found in about 3-5% of non-small-cell lung cancers. Dysregulation of the MET receptor leads to cell pro...